Appears On
Episode Appearances
Pharma and BioTech Daily · Jul 28, 2026
AstraZeneca's $80B Target Amid Setbacks? | Pharma and Biotech Daily
“Appointed as new CEO succeeding Doug Ingram; brings experience from ABB Vi and Tessera”
Antibody-Drug Conjugates (ADCs) in OncologyNon-Stimulant ADHD TherapeuticsDuchenne Muscular Dystrophy (DMD) Treatments
View Analysis